Lung
Dana-Farber Cancer Institute
Updates in KRAS G12C Mutant NSCLC: Demographics, Clinical Features, Genomics, and Treatment
FEATURING
Biagio Ricciuti
- 201 views
- January 8, 2024
- 1
ecancer
ESMO 2023 Insights: "Phase 2 KRYSTAL-7 Trial - Adagrasib+Pembro Combo for KRASG12C+, Treatment-Naïve, Advanced NSCLC"
FEATURING
Pasi Janne
- 87 views
- October 25, 2023
Insights from 2023 WCLC
WCLC 2023 Insights: "Mechanisms of Resistance to KRAS G12C Inhibitors in NSCLC"
FEATURING
Biagio Ricciuti
- 84 views
- October 9, 2023
- 1
Dana-Farber Cancer Institute
Small Cell Lung Cancer: A Brief Review of the Treatment Landscape
FEATURING
Jacob Sands
- 600 views
- November 8, 2021
- 3